



Foro Europeo sobre Política Farmacéutica

Maria Callejón


Directora General de Política de la PYME
Secretaría General de Industria

MITYC

24 de Octubre 2005




Ubicación geográfica de las empresas fabricantes de productos farmacéuticos en España






Actuales localizaciones extranjeras de I+D, 2004. (% respuestas)



Las futuras localizaciones extranjeras de I+D más atractivas, 2005-2009. (% de respuestas)






Figure 3 | Total health-care and pharmaceutical spending as a percentage of GDP in 2000. In US dollars. bn, billion; GDP, gross domestic product; tn, trillion. Based on data in REFS 20,21.



Fusiones y adquisiciones





Figure 1 | Deals, mergers and acquisitions in the biotechnology industry in the past 10 years. Biotechnology is now becoming an industry that is capable of supporting its own weight through intra-industry deals, as indicated by the increasing number of biotech-biotech deals, and the increasing fraction of the total number of deals involving biotech companies that these biotech-biotech deals represent. Data are from Decision Resources, Inc.



Gasto en I+D de las principales empresas inversoras en I+D de la UE-15 y EE.UU. en determinados sectores, 2002





Distribución del número de empresas biotecnológicas en España, por sector, 2004






Table 1 | **Venture funds established by pharmaceutical companies**

Company	Venture subsidiary	Year established	Approximate size of fund
Aventis and SG Asset Management (subsidiary of Société General)	Genavent	2000	US \$30 million
Eli Lilly	Lilly BioVentures	2001	US \$75 million
GlaxoSmithKline	SR One Ltd.	1985	US \$300 million
Johnson & Johnson	Johnson & Johnson Development Corporation	1973	Unknown
MedImmune	MedImmune Ventures	2002	US \$100 million
Merck	Merck Capital Ventures*	2000	US \$100 million
Novartis	Novartis BioVenture Fund [‡] Novartis Venture Fund	2000 1996	US \$100 million US \$170 million
Novo Nordisk	Novo A/S	2000	US \$200–300 million

*Merck Capital Ventures invests primarily in internet health-care companies. [‡]Novartis's BioVenture Fund focuses solely on US biotech. It is an extension of Novartis's Swiss-focused Venture Fund, which was established in 1996.



Políticas públicas

- **PROFIT (Programa de Fomento de la Investigación Tecnológica)**
- **Plan Profarma 2005-2008**
- **Fondo de Investigación biomédica (Instituto de Salud Carlos III)**
- **Ingenio 2010**
- **Torres Quevedo**

- **Financiación ENISA (Empresa Nacional de Innovación)**
 - **Préstamos participativos a 9 empresas biotecnología (3.1 M€)**
 - **Préstamos aprobados en fase de formalización a 3 empresas (2,1 M€)**